Completed PHASE3 INTERVENTIONAL 2-arm NCT01724801

Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer (BRAIN)

Phase III Study of Icotinib Treat the Patient With Brain Metastasis EGFR-mutant Non Small Cell Lung Cancer Comparing With Whole Brain Radiotherapy

Sponsor: Guangdong Association of Clinical Trials

Conditions Brain Metastasis Non Small Cell Lung Cancer

Interventions Icotinib whole brain radiation(WBI)

Updated 8 times since 2017 Last updated: Feb 28, 2017 Started: Oct 14, 2012 Primary completion: Jun 30, 2015 Completion: Sep 14, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01724801, this PHASE3 trial focuses on Brain Metastasis and Non Small Cell Lung Cancer and remains completed. Sponsored by Guangdong Association of Clinical Trials, it has been updated 8 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Dec 2019 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Dec 2019 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Mar 2017 — Jun 2018 [monthly]

Completed PHASE3

Status: Recruiting → Completed
Feb 2017 — Mar 2017 [monthly]

Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE3

First recorded

Oct 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Guangdong Association of Clinical Trials
Guangdong Provincial People's Hospital

Data source: Guangdong Association of Clinical Trials

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China